Cytokine augmentation of human immunodeficiency virus type 1 (HIV-1) gp120-specific cellular cytotoxicity.
Currently available anti-human immunodeficiency virus type 1 (HIV-1) agents such as azidothymidine can prevent de novo virus infection in vitro but lack significant activity against chronically infected cells. Our laboratory has recently described glycoprotein (gp)120-specific cell mediated cytotoxicity (CMC) present in HIV-1-seropositive individuals that is capable of destroying virally infected cells. As a means of potentially eliminating persistent reservoirs of HIV-1, we examined the ability of various cytokines to augment preexisting gp120-specific CMC activity of peripheral blood mononuclear cells obtained from early disease patients. We found that interferon-gamma alone had no effect on gp120 cellular reactivity; however, the combination of interferon-gamma plus IL-2 produced enhancement beyond that of IL-2 alone.
Stine
K C
KC
Department of Pediatrics, Duke University Medical Center, Durham, North Carolina.
Bolognesi
D
D
Weinhold
K J
KJ
D001685:Biological Factors / Q000494:pharmacology*; D016207:Cytokines; D003602:Cytotoxicity, Immunologic / Q000187:drug effects*; D015699:HIV Envelope Protein gp120 / Q000494:pharmacology*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007371:Interferon-gamma / Q000494:pharmacology; D007376:Interleukin-2 / Q000494:pharmacology; D007694:Killer Cells, Natural / Q000276:immunology; D014407:Tumor Cells, Cultured
D001685:Biological Factors; D016207:Cytokines; D015699:HIV Envelope Protein gp120; D007376:Interleukin-2; D007371:Interferon-gamma